Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

AZITHROMYCIN

All products: general benefit

Other products in the same Health Canada class (J01FA) — coverage varies; not interchangeable

  • Clarithromycin (Biaxin XL): general benefit, Not a benefit
  • Erythromycin base (Erythromid): general benefit, Not a benefit
  • Erythromycin estolate (Ilosone): general benefit, Not a benefit
  • Erythromycin ethylsuccinate (Ees-200): general benefit, Not a benefit

NRA-Azithromycin · DIN 02479680 · 250mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
NRA-Azithromycin · DIN 02479680 Manufacturer: Nora Pharma; listing date 2020-06-30 Health Canada: Marketed since 2019-05-07 · brand NRA-AZITHROMYCIN · ATC J01FA10 AZITHROMYCIN · form Tablet · route Oral · ingredients AZITHROMYCIN (AZITHROMYCIN DIHYDRATE) 250 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

NRA-Azithromycin: Formulary list price $0.9410/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9410 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96991 · Verify on the e-Formulary ↗ (DIN 02479680)

Source record
DIN 02479680: NRA-Azithromycin Raw flags: sec3=Y Item: 081212029; group id 19; item number 0030; lccId None; manufacturer id NRA Source form: Tab; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.9410; ministry $0.9410 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02479680 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96991
Interchangeable products
AG-Azithromycin · DIN 02480700 · $0.9410 Apo-Azithromycin · DIN 02247423 · $0.9410 Apo-Azithromycin Z · DIN 02415542 · $0.9410 Azithromycin · DIN 02330881 · $0.9410 Azithromycin · DIN 02442434 · $0.9410 Azithromycin · DIN 02545969 · $0.9410 Jamp-Azithromycin · DIN 02452308 · $0.9410 M-Azithromycin · DIN 02502038 · $0.9410 Mar-Azithromycin · DIN 02452324 · $0.9410 Novo-Azithromycin · DIN 02267845 · $0.9410 PMS-Azithromycin · DIN 02261634 · $0.9410 Riva-Azithromycin · DIN 02275309 · $0.9410 Sandoz Azithromycin · DIN 02265826 · $0.9410 Zithromax · DIN 02212021 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (08:12:12 Erythromycins) and how they are covered

Matched class: 08:12:12 Erythromycins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): CLARITHROMYCIN, ERYTHROMYCIN BASE, ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ETHYLSUCCINATE 08:12:12 Erythromycins

CLARITHROMYCIN

· 25 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), General benefit (15), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 500mg, 125mg/5mL, 250mg/5mL, 250mg · ER Tab, Ped Gran, Susp, Tab

ERYTHROMYCIN BASE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Tab

ERYTHROMYCIN ESTOLATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg/mL · O/L

ERYTHROMYCIN ETHYLSUCCINATE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 40mg/mL, 80mg/mL · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:12
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: disseminated mycobacterium avium complex
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. RIFABUTIN · Limited Use, codes 103, 104 (1), Temporary benefit (1) • the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection (CD4+ cell count 200/mm3 with an AIDS defining diagnosis, or CD4+ cell count  100/mm3 without an AIDS defining diagnosis). PM: https://pdf.hres.ca/dpd_pm/00073866.PDF; date SEPT 24, 2003; DIN 02063786; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications pms-AZITHROMYCIN (azithromycin) is indicated in adults for treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the following diseases and specific conditions. As recommended dosages, durations of therapy, and applicable patient populations vary among these infections, see 4 Dosage and Administration for specific dosing recommendations. Because some strains are resistant to azithromycin, when applicable, appropriate culture and susceptibility tests should be initiated before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with pms-AZITHROMYCIN may be initiated before results of these tests are known; once the results become available, antibiotic treatment should be adjusted accordingly. Pharyngitis and tonsillitis caused by Streptococcus pyogenes (group A β-hemolytic streptococci) occurring in individuals who cannot use first line therapy. NOTE: Penicillin is the usual drug of choice in the treatment of Streptococcus pyogenes pharyngitis, including the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of strep… https://pdf.hres.ca/dpd_pm/00085669.PDF PM date: AUG 7, 2026 Source product: PMS-AZITHROMYCIN; DIN 02261634; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.